menu
    • menu
    [{"orgOrder":0,"company":"GlycoEra","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GlycoEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GlycoEra \/ 5Am Ventures","highestDevelopmentStatusID":"3","companyTruncated":"GlycoEra \/ 5Am Ventures"},{"orgOrder":0,"company":"GlycoEra","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series B Financing","leadProduct":"GE8820","moa":"IgG4","graph1":"Immunology","graph2":"Preclinical","graph3":"GlycoEra","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"GlycoEra \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"GlycoEra \/ Novo Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals by GlycoEra

    Menu

    GlycoEra

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GlycoEra

                            Switzerland arrow
                            IMCAS Asia
                            Not Confirmed

                            GlycoEra

                            Switzerland arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GE8820

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $130.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            GlycoEra AG Raises $130 Million To Advance Protein Degraders for Autoimmune Diseases

                            Details : The financing aims to advance the clinical development of company's lead product GE8820, which is being evaluated for the autoimmune diseases such as pemphigus, primary membranous nephropathy etc.

                            Product Name : GE8820

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : GE8820

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Novo Holdings

                            Deal Size : $130.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GlycoEra

                            Switzerland arrow
                            IMCAS Asia
                            Not Confirmed

                            GlycoEra

                            Switzerland arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : 5Am Ventures

                            Deal Size : $49.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Inno...

                            Details : The proceeds will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease i...

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            May 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : 5Am Ventures

                            Deal Size : $49.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth